This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Investigations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Investigations may reveal:

  • MSU - sterile pyuria, haematuria

  • FBC - microcytic anaemia

  • U+Es - renal impairment

  • intravenous urography - this will demonstrate established papillary necrosis if present - this test is less used than previously

  • computerised tomography - this is said to be the most sensitive test for papillary necrosis (1)
    • however a study of patients with ESRD (National Analgesic Nephropathy Study [NANS]) in the United States evaluated the value of the non-contrast-enhanced CT as diagnostic test for AN
      • in this study the sensitivity of the noncontrast CT scan for the detection of analgesic-associated kidney injury was too low to be used as a routine test (3)

Reference:

  • 1) Elseviers MM, Waller I, Nenoy D et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with endstage renal failure: results of the ANNE study. Nephrol Dial Transplant 1995;10: 808-814.
  • 2) Prescribers' Journal 2000; 40 (2): 151-156
  • 3) Henrich WL, Clark RL, Kelly JP, Buckalew VM, Fenves A, Finn WF, Shapiro JI, Kimmel PL, Eggers P, Agodoa LE, Porter GA, Shapiro S, Toto R, Anderson T, Cupples LA, Kaufman DW : Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: Report of the national analgesic nephropathy study. J Am Soc Nephrol 2006; 17: 1472-1480

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.